OLD Mission Capital LLC bought a new position in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 156,592 shares of the company's stock, valued at approximately $3,545,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Callan Family Office LLC bought a new stake in Fresenius Medical Care during the 4th quarter worth about $502,000. Callan Capital LLC bought a new stake in shares of Fresenius Medical Care during the fourth quarter valued at approximately $297,000. Sanctuary Advisors LLC acquired a new stake in shares of Fresenius Medical Care in the fourth quarter valued at approximately $983,000. ABC Arbitrage SA bought a new position in Fresenius Medical Care in the 4th quarter worth approximately $4,215,000. Finally, Verition Fund Management LLC acquired a new position in Fresenius Medical Care during the 3rd quarter worth $237,000. 8.37% of the stock is currently owned by institutional investors and hedge funds.
Fresenius Medical Care Trading Down 6.7 %
Shares of FMS stock traded down $1.72 during trading hours on Friday, reaching $23.94. The company had a trading volume of 488,322 shares, compared to its average volume of 315,246. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $25.96. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm has a market cap of $14.05 billion, a price-to-earnings ratio of 19.79, a P/E/G ratio of 0.76 and a beta of 0.93. The company has a 50 day moving average of $24.14 and a 200 day moving average of $22.67.
Analyst Ratings Changes
A number of research firms have recently weighed in on FMS. StockNews.com upgraded Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Truist Financial boosted their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a report on Monday, January 6th.
Get Our Latest Analysis on FMS
Fresenius Medical Care Profile
(
Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Articles
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
